This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
Cancer Chemotherapy and Pharmacology Open Access 02 February 2021
-
CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial
Cancer Communications Open Access 24 May 2019
-
Role and Mechanism of Galactose-Alpha-1,3-Galactose in the Elicitation of Delayed Anaphylactic Reactions to Red Meat
Current Allergy and Asthma Reports Open Access 23 January 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Qian, J. et al. Anal. Biochem. 364, 8–18 (2007).
Chung, C.H. et al. N. Engl. J. Med. 358, 1109–1117 (2008).
Jacquenet, S., Moneret-Vautrin, D.A. & Bihain, B.E. J. Allergy Clin. Immunol. 124, 603–605 (2009).
Commins, S.P. et al. J. Allergy Clin. Immunol. 123, 426–433 (2009).
Ashford, D.A. et al. J. Biol. Chem. 268, 3260–3267 (1993).
Bosques, C.J. et al. Nat. Biotechnol. 28, 1153–1156 (2010).
Vultaggio, A. et al. Allergy 65, 657–661 (2010).
Jefferis, R. Biotechnol. Prog. 21, 11–16 (2005).
Smith, D.F. et al. J. Biol. Chem. 265, 6225–6234 (1990).
Jones, A.J. et al. Glycobiology 17, 529–540 (2007).
Acknowledgements
We thank M. Geukes, A.H. Simmelink and N.I.L. Derksen for valuable technical assistance, and R. Taylor for his enthusiastic support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.J.L.v.B., S.V., P.H.C.v.B, J.G.J.v.d.W. and P.W.H.I.P. are Genmab employees and Genmab warrants and/or stock. T.R. has received research support rhgouh his institution from Genmab.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5, Supplementary Tables 1 and 2, and Supplementary Methods (PDF 1046 kb)
Rights and permissions
About this article
Cite this article
van Bueren, J., Rispens, T., Verploegen, S. et al. Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol 29, 574–576 (2011). https://doi.org/10.1038/nbt.1912
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1912
This article is cited by
-
Alpha-Gal-Syndrom
Der Hautarzt (2022)
-
Hypersensitivity and Immune-related Adverse Events in Biologic Therapy
Clinical Reviews in Allergy & Immunology (2021)
-
Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo
Clinical and Translational Oncology (2021)
-
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
Cancer Chemotherapy and Pharmacology (2021)
-
Hypersensitivity Reactions to Biologicals: from Bench to Bedside
Current Treatment Options in Allergy (2020)